A randomized comparison of intradermal and intramuscular vaccination against hepatitis B virus in incident chronic hemodialysis patients

American Journal of Kidney Diseases

Volumn 36, Issue 5, 2000, Pages 976-982

  Charest, Andre F ^a   McDougall, James ^a   Goldstein, Marc B ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Chronic hemodialysis (HD); Duration of immunity; Hepatitis B vaccination; Hepatitis B virus (HBV); Seroconversion

Indexed keywords

HEPATITIS B VACCINE;

ADULT; ANTIBODY RESPONSE; ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEMODIALYSIS; HEPATITIS B; HUMAN; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION;

EID: 0033765040     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/ajkd.2000.19099     Document Type: Article

References (30)

1. Hemodialysis-associated hepatitis in the United States, 1974
2. Decrease in the incidence of hepatitis in dialysis units associated with prevention program
3. A common-source outbreak of fulminant hepatitis B in hemodialysis patients induced by precore mutant
4. Recombinant versus plasma-derived hepatitis B vaccines: Issues of safety, immunogenicity and cost-effectiveness
5. The Latium Hepatitis Prevention Group. Evaluation of a region-wide hepatitis B vaccination program in dialysis patients: Experience in an Italian region
6. Vaccination against hepatitis B in high-risk hemodialysis units: A double blind study
7. Active hepatitis B vaccination of dialysis patients and medical staff
8. Seroresponse to hepatitis B vaccine in patients and staff of renal dialysis centers, Wisconsin
9. Effects of different dose levels and vaccination schedules on immune response to recombinant DNA hepatitis B vaccine in hemodialysis patients
10. Duration of hepatitis B surface antigenemia (HBsAg) in hemodialysis patients
11. Host responses to hepatitis B infection in patients in a chronic hemodialysis unit
12. Local low dose interleukin 2 therapy induces systemic immune responses against HbsAg in immunodeficient non-responders to hepatitis B vaccination: A controlled pilot trial
13. Protective effect of hepatitis B vaccine in chronic hemodialysis patients
14. Successful vaccination with intradermal hepatitis B vaccine in hemodialysis patients previously nonresponsive to intramuscular hepatitis B vaccine
15. Complete seroconversion by low dose intradermal injection of recombinant hepatitis B vaccine in hemodialysis patients
16. Duration of immunity after hepatitis B vaccination: Efficacy of low-dose booster vaccine
17. Duration of immunogenicity and efficacy of hepatitis B vaccine in Yupik Eskimo population
18. Reinforced intradermal hepatitis B vaccination in hemodialysis patients is superior in antibody response to intramuscular or subcutaneous vaccination
19. Low-dose intradermal versus intramuscular hepatitis B vaccination in patients with end-stage renal failure: A preliminary study
20. Immunogenicity and efficacy of anti-hepatitis B vaccines in hemodialysis patients
21. Persistence of antibodies following vaccination with a yeast-derived recombinant hepatitis B vaccine
22. The relationship of dialysis adequacy to immune responsiveness and hepatitis B vaccination in hemodialysis patients
23. The influence of nutritional status, dialysis adequacy, and residual renal function on the response to hepatitis B vaccination in peritoneal dialysis patients
24. Comparison of the response to the recombinant vaccine against hepatitis B virus in dialyzed and nondialyzed children with CRF using different doses and routes of administration
25. Increasing serum creatinine and age reduce the response to hepatitis B vaccine in renal failure patients
26. Hepatitis B vaccines in patients with chronic renal failure before dialysis
27. Obesity as a predictor of poor antibody response to hepatitis B plasma vaccine
28. Long-term immunogenicity and efficacy of hepatitis B vaccine in hemodialysis patients